Valopicitabine dihydrochloride: A specific polymerase inhibitor of hepatitis C virus

Current Opinion in Investigational Drugs

Volumn 8, Issue 2, 2007, Pages 150-158

  Toniutto, Pierluigi ^a   Fabris, Carlo ^a   Bitetto, Davide ^a   Fornasiere, Ezio ^a   Rapetti, Rachele ^a   Pirisi, Mario ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VALOPICITABINE;

CLINICAL TRIAL; DEHYDRATION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; GASTROENTERITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY FAILURE; MONOTHERAPY; NAUSEA AND VOMITING; NONHUMAN; PANCREATITIS; REVIEW;

ANIMALS; CLINICAL TRIALS, PHASE II; DNA-DIRECTED RNA POLYMERASES; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR STRUCTURE; PYRIMIDINE NUCLEOSIDES;

EID: 33947309390     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. 478931 Idenix Research. Idenix Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2003 February 17
2. 485185 NM-283 shows promise. Idenix Pharmaceuticals Inc PRESS RELEASE 2003 April 09
3. 508920 Sirna Therapeutics - Setting the plan in motion. Sirna Therapeutics Inc ANNUAL REPORT 2003 May 29
4. 511549 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A et al N ENGL J MED 2002 347 13 975-982
5. 513647 Future Antivirals - SMi Conference, Latest developments in HIV, Hepatitis, Herpes, Influenza, RSV and SARS, London, UK Harrison R IDDB MEETING REPORT 2003 November 12-13
6. 514125 NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee. Standring DN, Lanford R, Wright T, Chung RT, Bichko V, Cretton-Scott E, Pan-Zhou X, Bergelson S, Qu L, Tausek M, Bridges E et al J HEPATOL 2003 2 Abs 3
7. 538687 A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283, a novel antiviral treatment for hepatitis C. Godofsky E, Afdhal NH, Rustgi V, Shick L, Duncan L, Zhou XJ, Chao G, Fang C, Fielman B, Myers M, Brown N GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs 1020 •• This abstract reports the first clinical data for valopicitabine dihydrochloride. In this phase I/II dose-escalation trial, patients were treated with valopicitabine dihydrochloride ranging from 50 to 400 mg/day. Dose-related decreases in serum HCV RNA were observed.
8. 539033 Idenix Pharmaceuticals Inc announces first human clinical trial data for NM283 for the treatment of hepatitis C. Idenix Pharmaceuticals Inc PRESS RELEASE 2004 May 18
9. 563621 First clinical results for a novel antiviral treatment for hepatitis C: A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283. Godofsky E, Afdhal N, Rustgi V, Shick L, Duncan L, Zhou XJ, Chao G, Fang C, Fielman B, Myers M, Brown NA J HEPATOL 2004 40 Suppl 1 35 •• In this phase I/II clinical trial, escalating doses of valopicitabine dihydrochloride (50 to 400 mg/day) were well tolerated with no serious adverse events, DLTs or pattern of laboratory abnormalities.
10. 567853 Idenix's NM-283 reduces HCV viral load in combination with PEGylated interferon. Idenix Pharmaceuticals Inc PRESS RELEASE 2004 November 01
11. 568262 Idenix Pharmaceuticals announces third quarter and nine month financial results. Idenix Pharmaceuticals Inc PRESS RELEASE 2004 November 02
12. 570841 Japan Tobacco Inc clinical development. Japan Tobacco Inc COMPANY WORLD WIDE WEB SITE 2003 September 16
13. 578943 Isis tightens belt for 2005. Isis Pharmaceuticals Inc PRESS RELEASE 2005 10 January
14. 579005 Idenix reports positive phase IIa results for HCV drug. Idenix Pharmaceuticals Inc PRESS RELEASE 2005 January 10
15. 595098 Idenix's HCV therapy reduces serum virus levels in phase IIa study. Idenix Pharmaceuticals Inc PRESS RELEASE 2005 April 14
16. 623777 Japan Tobacco Inc. Clinical development. Japan Tobacco Inc COMPANY WORLD WIDE WEB SITE 2005 August 01
17. 634092 Valopicitabine (NM283) combined with pegylated interferon demonstrated significantly greater suppression of hepatitis C virus (HCV) replication in treatment-refractory patients compared to retreatment with ribavirin plus pegylated interferon. Idenix Pharmaceuticals Inc PRESS RELEASE 2005 November 11
18. 634310 Schering-Plough's HCV protease inhibitor safe and effective in phase I trials. Schering-Plough Corp PRESS RELEASE 2005 14 November
19. 640132 American Association for the Study of Liver Diseases (AASLD) - 56th Annual Meeting (Part I), San Francisco, CA, USA, 11-15 November 2005. Phend C IDDB MEETING REPORT 2005 November 11-15
20. 640570 Idenix's valopicitabine suppresses HCV replication in phase IIb study. Idenix Pharmaceuticals Inc PRESS RELEASE 2005 December 14
21. 644094 Idenix Pharmaceuticals reports positive 4-week data from a phase IIb clinical trial evaluating valopicitabine (NM283) combined with pegylated interferon in treatment-naive hepatitis C patients. Idenix Pharmaceuticals Inc PRESS RELEASE 2006 January 09
22. 645327 Vertex Pharmaceuticals Inc JP MORGAN ANNUAL HEALTHCARE CONFERENCE 2006 24 9-12 Suppl
23. 652504 Roche Holding AG - product pipeline. Roche Holding AG COMPANY WORLD WIDE WEB SITE 2005 31 December
24. 657654 Idenix reduces phase II HCV drug dose due to GI side effects. Idenix Pharmaceuticals Inc PRESS RELEASE 2006 March 23
25. 658432 Idenix announces licensing of valopicitabine (NM283) by Novartis. Idenix Pharmaceuticals Inc PRESS RELEASE 2006 March 29
26. 662618 Schering-Plough expands phase II SCH-503034 HCV trial. Schering-Plough Corp PRESS RELEASE 2006 20 April
27. 664719 Favorable antiviral activity and improved tolerability demonstrated by valopicitabine 200 mg/day in combination with pegylated interferon in an ongoing phase IIb trial in treatment-naive genotype 1 patients. Idenix Pharmaceuticals Inc PRESS RELEASE 2006 April 29
28. 667980 Investor relations: SG Cowen Presentation - Idenix Pharmaceuticals: Building a leading antiviral franchise. Idenix Pharmaceuticals Inc COMPANY PRESENTATION 2006 March 06
29. 673701 Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alfa therapy. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS SCIENCE 1998 282 5386 103-107
30. 720923 NCT00367887: A study evaluating the safety and clinical activity of HCV-796 in treatment-naive and non-responder subjects. Wyeth INTERNET SITE 2006 September 21 www.clinicaltrials.gov
31. 731316 Roche's R-1626 enters phase II and gets Fast Track status for HCV. Roche Holding AG PRESS RELEASE 2006 October 16
32. 733379 NM 283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Pierra C, Benzaria S, Amador A, Moussa A, Mathieu S, Storer R, Gosselin G NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS 2005 24 5-7 767-770
33. 733380 Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: Results from a phase I/II dose-escalation trial in patients with HCV-1 infection. Zhou XJ, Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McInery D, Fielman BA, Brown NA J HEPATOL 2005 42 Suppl 2 229 • In this phase I/II clinical trial, orally administered valopicitabine dihydrochloride (50 to 800 mg/day) was well absorbed, drug levels were proportional to the dose and there was no significant drug accumulation.
34. 733390 Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Coelmont L, Paeshuyse J, Windisch MP, De Clercq E, Bartenschlager R, Neyts J ANTIMICROB AGENTS CHEMOTHER 2006 50 10 3444-3446 •• This interesting study shows the interaction between ribavirin and valopicitabine dihydrochloride in antagonizing HCV replication in vitro. Data demonstrate that at pharmacological concentrations ribavirin was able to antagonize the antiviral effect of valopicitabine dihydrochloride.
35. 733391 Valopicitabine (NM283) plus peg-interferon for chronic hepatitis C in treatment naive and nonresponder patients: Interim phase IIb results. Sherman KE, Lawitz E, O'Brien CB J CLIN VIROL 2006 36 Suppl 2 S24
36. 733401 A nucleoside inhibitor of hepatitis C virus replication efficiently inhibits the replication of flaviviruses in vitro. Leyssen P, De Lamballerie X, De Clercq E, Neyts J ANTIVIR RES 2006 70 1 A80
37. 733402 Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (pegIFN/RBV) re-treatment in hepatitis C patients with prior non-response to pegIFN/RBV: Week 24 results. Afdhal N, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, Sherman K J HEPATOL 2006 44 Suppl 2 S19 •• This phase IIb clinical trial compared the antiviral efficacy of valopicitabine dihydrochloride plus PEG-IFN with PEG-IFN plus ribavirin in a group of HCV-positive treatment-refractory patients. After 24 weeks of treatment, a significantly higher decrease in mean circulating HCV RNA was observed in patients treated with valopicitabine
38. 733404 Long-term study of NM283 (valopicitabine) resistance using bovine viral diarrhea virus. Bichko V, LaColla M, Tausek MM, Lallos L, Gillum G, Qu L, Sommadossi JP, Standring DN J HEPATOL 2006 44 Suppl 2 S152 •• This abstract describes the emergence of a BVDV mutation (equivalent to a S282T mutation in HCV polymerase) during prolonged treatment with valopicitabine dihydrochloride.
39. 733408 Safety and pharmacokinetics of NM107 following intravenous infusion of escalating doses in healthy volunteers: Determination of absolute oral bioavailability of valopicitabine (NM283). Zhou XJ, Knox S, Fielman B, Chao G, Brown N J HEPATOL 2006 44 Suppl 2 S231-S232
40. 733410 Absence of effect of pegylated interferon α-2b on the pharmacokinetics of valopicitabine (NM283) in patients with chronic hepatitis C. Zhou XJ, Fielman B, Chao G, Knox S, Brown N J HEPATOL 2006 44 Suppl 2 S232 A624
41. 733411 Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-interferon in treatment-naive patients with HCV-1 infection: First results from a phase IIb trial. Dicterich A, Lawitz E, Nguyen T Younes Z, Santoro J, Gitlin N, McEniry D, Chasen R, Goff J, Knox S, Kleber K et al J HEPATOL 2006 44 Suppl 2 S271 A736
42. 733413 Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: Results from a phase I/II dose-escalation trial in patients with HCV-1 infection. Zhou XJ, Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, Duncan L, Constance BF Chao G, Brown NA GASTROENTEROLOGY 2005 128 4 Suppl 2 A700
43. 733414 Valopicitabine (NM283) alone and in combination with PEG-interferon in patients with genotype 1 chronic hepatitis C: Preliminary results from an ongoing phase II, multicenter study. Rodriguez-Torres M, Lawitz E, Godofsky E, Afdhal N, Chao G, Constance BF, Knox S, Brown NA GASTROENTEROLOGY 2005 128 4 Suppl 2 A695-A696 • This phase II clinical trial investigated the antiviral effect of valopicitabine dihydrochloride monotherapy in comparison with patients treated with valopicitabine dyhidrochloride plus PEG-IFNα2b in HCV-infected patients. A more pronounced HCV viral decline was observed in patients treated with the combination therapy.
44. 733416 Characterization of NM283 (valopicitabine) resistance profile using bovine viral diarrhea. Bichko V, Qu L, La Colla M, Tausek M, Bergelson S, Pierra C, Storer R, Gosselin G, Sommadossi JP HEPATOLOGY 2005 42 4 Suppl 1 A543
45. 733417 Randomized trial of valopicitabine (NM283), alone or with peginterferon, vs retreatment with peg-interferon plus ribavirin (PegIFN/RBV) in hepatitis C patients with previous non-response to PegIFN/RBV: First interim results. O'Brien C, Godofsky E, Rodriguez-Torres M, Afdhal N, Pappas SC, Pockros P, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, Sherman K et al HEPATOLOGY 2005 42 4 Suppl 1 A234
46. 733421 Enhanced antiviral efficacy for valopicitabine (NM283) plus peginterferon in hepatitis C patients with HCV genotype-1 infection: Results of a phase lla multicenter trial. Afdhal N, Rodriguez-Torres M, Lawitz E, Godofsky E, Choa G, Fielman B, Knox S, Brown N J HEPATOL 2005 42 Suppl 2 39-40
47. 735359 Novartis and Idenix's valopicitabine plus PEG-INF reduces HCV in phase IIb trial. Idenix Pharmaceuticals Inc PRESS RELEASE 2006 October 27
48. 748199 Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2-C- methylcytidine. Pierra C, Amador A, Benzaria S, Cretton-Scott E, D'Amours M, Mao J, Mathieu S, Moussa A, Bridges EG, Standring DN, Sommadossi JP et al J MED CHEM 2006 49 22 6614-6620 •• This study describes the mechanisms adopted for the synthesis of valopicitabine dihydrochloride and shows in detail the main pharmacokinetic characteristics of the drug in animal models.
49. 748850 Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: Antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D, Zhou XJ, Chao G, Fang C, Fielman B, Myers M et al HEPATOLOGY 2004 40 4 Suppl 1 Abs 726 LB03
50. 751209 Vertex's telaprevir gives high response rate in phase II HCV infection trial. Vertex Pharmaceuticals Inc PRESS RELEASE 2006 13 December
51. 751267 Management of hepatitis C in liver transplant recipients. Kuo A, Terrault NA AM J TRANSPL 2006 6 3 449-458
52. 751281 Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M et al HEPATOLOGY 2005 42 4 962-973
53. 751282 Hepatitis C vaccines: Inducing and challenging memory T cells. Shiina M, Rehermann B HEPATOLOGY 2006 43 6 1395-1398
54. 751298 Antiviral treatment of hepatitis C. Toniutto P, Fabris C, Pirisi M EXPERT OPIN PHARMACOTHER 2006 7 15 2025-2035
55. 751299 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M LANCET 2001 358 9286 958-965
56. 751305 National Institutes of Health Consensus Conference Statement: Management of hepatitis C. HEPATOLOGY 2002 36 5 Suppl 1 S3-S20
57. 755227 World Health Organization. Global distribution of hepatitis A, B and C, 2001. WEEKLY EPIDEMIOLOGICAL RECORD 2002 77 6 41-48
58. 755228 Hepatitis C virus (HCV) infection in a community in the Nile Delta: Population description and HCV prevalence. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Thomas D, Fix AD, Strickland GT, Anwar W et al HEPATOLOGY 2000 32 1 111-115